Pirbright has been awarded £100,000 to support innovative research and promote knowledge exchange.
This funding was given by UK Research and Innovation (UKRI) in its Impact Acceleration Account (IAA) which aims to support early-stage translation of UK research to have real-life impact.
Pirbright research shows that immunity to SARS-CoV-2, the virus that causes COVID-19, decreases over time after vaccination, but that booster vaccinations can help restore immunity and help the immune system recognise new variants of the virus, including Omicron.
Vaccination against SARS-CoV-2 has been pivotal in protecting people across the world, especially older adults and the vulnerable, preventing serious disease and hospitalisations.
Pirbright was one of just 16 exhibits selected to attend the prestigious Royal Society Summer Science Exhibition 2022 which showcased cutting-edge science for people of all ages.
® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.
